AbbVie Chart Reflects Bearish Signals Ahead Of Q3 Earnings
Portfolio Pulse from Surbhi Jain
AbbVie Inc (NYSE:ABBV) is set to report its Q3 earnings with expected EPS of $2.92 and revenues of $14.28 billion. Ahead of this, AbbVie acquired Aliada Therapeutics for $1.4 billion to enhance its Alzheimer's research. The stock shows mixed technical signals, with a short-term bearish trend but potential for a bullish turn. Analysts see a 10.58% upside with a price target of $210.
October 29, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie is preparing to report Q3 earnings with expectations of $2.92 EPS and $14.28 billion in revenue. The company recently acquired Aliada Therapeutics for $1.4 billion to boost its Alzheimer's research. Technical indicators show a mixed outlook, with short-term bearish signals but potential for a bullish turn. Analysts have a positive outlook with a 10.58% upside.
AbbVie's acquisition of Aliada Therapeutics is a strategic move to enhance its Alzheimer's research, which could positively impact its stock. The technical indicators show a mixed outlook, but the potential for a bullish turn and positive analyst ratings suggest a likely short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100